NASDAQ · Biotechnology

AGIO (AGIO) Stock

$31.72 +0.38% NASDAQ: AGIO Healthcare

Valuation

MetricValue
Price$31.72
Market Cap$1.89B
P/E Ratio-3.56
P/B Ratio1.24
P/S Ratio25.40
EPS (TTM)$-7.12
52-Week High$46.00
52-Week Low$22.24
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-34.62%
ROA-31.84%
ROCE-39.56%
Gross Margin-874.07%
Operating Margin-874.07%
Net Margin-6.40%
Debt/Equity0.03
Current Ratio11.49

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$14.0M$27.0M$36.0M$54.0M
Operating Profit$-378.0M$-389.0M$-391.0M$-426.0M$-472.0M
Net Profit$1.6B$-232.0M$-352.0M$674.0M$-413.0M
EPS$-6.36$-4.23$-6.33$11.64$-7.12
Op Margin—-2732.1%-1459.5%-1166.5%-873.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.4B$1.2B$937.0M$1.7B$1.3B
Total Liabilities$146.0M$138.0M$126.0M$122.0M$104.0M
Cash$203.0M$139.0M$88.0M$76.0M$89.0M
Borrowings$97.0M$86.0M$72.0M$57.0M$62.0M

Latest News

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week Motley Fool · Jul 10, 2026 Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? Simply Wall St. · Jul 9, 2026 Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease Simply Wall St. · Jul 9, 2026 AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up Zacks · Jul 8, 2026 Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? Zacks · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-407.0M$-309.0M$-296.0M$-390.0M$-373.0M
Investing Cash Flow$1.2B$238.0M$239.0M$362.0M$373.0M
Financing Cash Flow$-765.0M$0$0$0$0
Net Cash Flow$76.0M$-64.0M$-51.0M$-12.0M$13.0M
Free Cash Flow$-413.0M$-314.0M$-297.0M$-392.0M$-377.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-22.93%
Quick Ratio13.59
Interest Coverage—
Return 1Y-9.10%
Return 3Y31.00%
Return 5Y-28.17%

Ownership

Insiders Held1.12%
Institutions Held109.27%
Institutions Float Held110.51%
Institutional HolderSharesReport Date
Blackrock Inc.5,754,9572026-03-31
Farallon Capital Management LLC5,684,0002026-03-31
State Street Corporation3,364,8792026-03-31
Armistice Capital, LLC2,716,0002026-03-31
Erste Asset Management GmbH2,704,9002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About AGIO

AGIO is led by CEO Brian Goff, employs 486 people, headquartered in US, publicly traded since 2013.

AGIO stock trades at $31.72 with a market capitalization of $1.89B. The stock is valued at a price-to-earnings (P/E) ratio of -3.56, price-to-book of 1.24, price-to-sales of 25.40. Over the past 52 weeks the stock has ranged between $22.24 and $46.00, and currently trades 31.0% below its 52-week high.

On profitability, AGIO generates a return on equity (ROE) of -34.62%, return on capital employed of -39.56%, an operating margin of -874.07%, a net profit margin of -6.40%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides